Astellas Signs Agreement With NeurogesX For Qutenza
This article was originally published in PharmAsia News
Executive SummaryAstellas June 23 signed a licensing agreement with U.S. biotech NeurogesX and obtained exclusive rights to distribute, develop and market Qutenza in Europe, the Middle East and Africa. Astellas subsidiary Astellas Europe will pay 30 million euros in a one-time payment and will pay 5 million euros for the option to co-develop and co-market NGX-1998. Qutenza is an agent to relieve pain associated with peripheral neuropathic pain conditions. It obtained an approval from the European Medicines Agency for non-diabetic pain relief this May. (Click here for more - Japanese language
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.